Vanessa Carle - 14 May 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Secretary
Signature
/Vanessa Carle/
Issuer symbol
LEXX
Transactions as of
14 May 2024
Net transactions value
+$2,875
Form type
4
Filing time
15 May 2024, 17:37:12 UTC
Previous filing
10 May 2024
Next filing
01 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LEXX common shares Options Exercise $2,875 +2,500 +3731% $1.15 2,567 14 May 2024 Direct
holding LEXX common shares 67 14 May 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Options Exercise $0 -2,500 -4% $0.000000 60,067 14 May 2024 Common Shares 2,500 $1.15 Direct
holding LEXX Warrants 67 14 May 2024 Common Shares 67 $36.00 Direct
holding LEXX Stock Options 12,567 14 May 2024 Common Shares 12,500 $3.00 Direct F1
holding LEXX Stock Options 17,567 14 May 2024 Common Shares 5,000 $3.00 Direct F2
holding LEXX Stock Options 27,567 14 May 2024 Common Shares 10,000 $3.00 Direct F3
holding LEXX Stock Options 40,067 14 May 2024 Common Shares 12,500 $2.91 Direct
holding LEXX Stock Options 52,567 14 May 2024 Common Shares 12,500 $1.15 Direct
holding LEXX Stock Options 62,567 14 May 2024 Common Shares 10,000 $2.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received May 9, 2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023